ACAD

$0.00

(

0.00%

)
Quote details

stock

ACADIA Pharmaceuticals Inc

NASDAQ | ACAD

20.95

USD

0.00

(

0.00%

)

AT CLOSE (AS OF Jul 3, 2025)

$3.5B

MARKET CAP

15.29

P/E Ratio

1.37

EPS

$25

52 Week High

$13

52 Week Low

LIFE SCIENCES

Sector

ACAD Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

ACAD Technicals

Tags:

ACAD Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $876M
Total Revenue $958M
Cost Of Revenue $82M
Costof Goods And Services Sold $82M
Operating Income $231M
Selling General And Administrative $488M
Research And Development $303M
Operating Expenses $645M
Investment Income Net -
Net Interest Income $25M
Interest Income $25M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $16M
Income Before Tax $258M
Income Tax Expense $32M
Interest And Debt Expense -
Net Income From Continuing Operations $226M
Comprehensive Income Net Of Tax -
Ebit $84M
Ebitda $100M
Net Income $226M

Revenue & Profitability

Earnings Performance

ACAD Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $938M
Cash And Cash Equivalents At Carrying Value $320M
Cash And Short Term Investments $320M
Inventory $22M
Current Net Receivables $105M
Total Non Current Assets $249M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $120M
Intangible Assets Excluding Goodwill $120M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $436M
Other Current Assets $56M
Other Non Current Assets -
Total Liabilities $455M
Total Current Liabilities $395M
Current Accounts Payable $16M
Deferred Revenue -
Current Debt -
Short Term Debt $10M
Total Non Current Liabilities $60M
Capital Lease Obligations $52M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $52M
Other Current Liabilities $357M
Other Non Current Liabilities $18M
Total Shareholder Equity $733M
Treasury Stock -
Retained Earnings -$2.2B
Common Stock $16K
Common Stock Shares Outstanding $166M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $158M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $16M
Capital Expenditures $523K
Change In Receivables -
Change In Inventory -$50M
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $6.8M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $226M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $876M
Total Revenue $958M
Cost Of Revenue $82M
Costof Goods And Services Sold $82M
Operating Income $231M
Selling General And Administrative $488M
Research And Development $303M
Operating Expenses $645M
Investment Income Net -
Net Interest Income $25M
Interest Income $25M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $16M
Income Before Tax $258M
Income Tax Expense $32M
Interest And Debt Expense -
Net Income From Continuing Operations $226M
Comprehensive Income Net Of Tax -
Ebit $84M
Ebitda $100M
Net Income $226M

ACAD News

ACAD Profile

ACADIA Pharmaceuticals Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.

Discover more tools and features to empower your trading
Explore Features

Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.